Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
OHSU Knight Cancer Institute
University of Chicago
Dana-Farber Cancer Institute
Acerta Pharma BV
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital
University of California, San Diego
National Institutes of Health Clinical Center (CC)
AbbVie
Cedars-Sinai Medical Center
Pfizer
OrphAI Therapeutics
Fate Therapeutics
Fate Therapeutics
Mayo Clinic
M.D. Anderson Cancer Center
AbbVie
MEI Pharma, Inc.
M.D. Anderson Cancer Center
Brown University
University of California, Davis
Celgene
Aptevo Therapeutics
Gilead Sciences
M.D. Anderson Cancer Center
Genentech, Inc.
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Swiss Cancer Institute
Hoffmann-La Roche
Wake Forest University Health Sciences
Dartmouth-Hitchcock Medical Center
Duke University
Georgetown University
National Institutes of Health Clinical Center (CC)
Aptevo Therapeutics
Genentech, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute